uPAR Cancer Research Results

uPAR, Urokinase-type plasminogen activator receptor: Click to Expand ⟱
Source:
Type:
uPAR is a target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours.
uPAR is typically overexpressed in breast cancer tissues relative to normal breast epithelium. • Prognosis:
– High uPAR levels correlate with increased invasiveness, higher grades, and an overall poorer prognosis.
• Function:
– uPAR contributes to tumor cell migration and invasion, supporting a protumor role.

uPAR is considered protumor because its overexpression facilitates extracellular matrix degradation, enhances cell migration/invasion, and supports signaling pathways that promote tumor progression.
Scientific Papers found: Click to Expand⟱
9185- BITC,  PEITC,  AITC,  ITCs,    Effects of Brassicaceae Isothiocyanates on Prostate Cancer
- Review, Pca, NA
antiOx↑, Inflam↓, Bacteria↓, chemoPv↑, TumCCA↑, Apoptosis↑, ChemoSen↑, TumCP↓, TumCI↓, TumMeta↓, DNMTs↓, HDAC↓, HDAC6↓, AR↓, selectivity↑, CDK1↓, CycB/CCNB1↓, P53↑, WEE1↑, CDC25↓, cMyc↓, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓, XIAP↓, survivin↓, Bcl-2↓, compIII↓, APAF1↑, ROS↑, OXPHOS↓, MMP↓, Ca+2↑, CXCR4↓, IL6↓, JAK2↓, STAT3↓, mTOR↓, Synergy↑, CSCs↓, uPAR↓, NF-kB↓, TGF-β↓, angioG↓,
8972- BRice,    Cyanidin-3-O-Glucoside-Rich Black Rice Fraction Attenuates IL-1β/IL-6-Driven A549 Lung Cancer Cell Migration and Invasion and Modulates JAK1/STAT3 Signaling
- in-vitro, Lung, A549
Ingr↝, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, uPA↓, uPAR↓, p‑JAK1↓, p‑STAT3↓, Dose↝,
8840- DIM,    Inactivation of uPA and its receptor uPAR by 3, 3'-Diindolylmethane (DIM) leads to the inhibition of Prostate Cancer Cell growth and migration
- in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B - in-vitro, Pca, PC3
uPA↓, uPAR↓, TumCG↓, TumCMig↓, VEGF↓, MMP9↓,
8845- DIM,  I3C,    3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
- Review, Var, NA
*BioAv↝, *BioAv↓, *BioAv↓, *AntiAg↑, *ROS↓, *AntiThr↑, *Stroke↓, *CYP1A1↑, *CYP1A2↑, *GSTs↑, *NQO1↑, AntiTum↑, AntiCan↑, TumAuto↓, Let-7↑, miR-34a↑, TumCMig↓, Apoptosis↑, MMP↓, mtDam↑, ROS↑, TumCCA↑, other↝, PSA↓, Dose↝, MMP2↓, MMP3↓, MMP9↓, EGFR↓, RAS↓, PI3K↓, Akt↓, mTOR↓, CDK4↓, cycD1/CCND1↓, P21↑, MDM2↓, TumCP↓, NF-kB↓, RANKL↓, PUMA↓, Wnt↓, MTA2↓, EZH2↓, AhR↓, PTEN↑, NOTCH1↓, IRAK1↓, p27/CDKN1B↓, CDKN1C/p57↓, CDC25↓, EGFR↓, Zeb1↓, FOXM1↓, SOX4↓, E-cadherin↑, uPA↓, uPAR↓,
8885- MOR,    Anti-Inflammatory and Anti-Migratory Effects of Morin on Non-Small-Cell Lung Cancer Metastasis via Inhibition of NLRP3/MAPK Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
IL1β↓, IL18↓, IL6↓, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, uPAR↓, uPA↓, EMT↓, Fibronectin↓, N-cadherin↓, Vim↓, NLRP3↓, MAPK↓,
6491- Nimb,    Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells
- Review, PC, NA
eff↑, uPA↓, uPAR↓, p‑EGFR↓, VEGFR1↓, NF-kB↓, IKKα↓, MMP2↓, MMP9↓, TIMP2↑, TumCP↓, IGFR↓, Akt↓, ERK↓, TumCCA↓, BAX↑, BAD↑, FasL⇅, Cyt‑c↑, EPR↑,
8425- OM,    Anti-metastatic and anti-tumor growth effects of Origanum majorana on highly metastatic human breast cancer cells: inhibition of NFκB signaling and reduction of nitric oxide production
- vitro+vivo, BC, MDA-MB-231
TumCCA↑, Apoptosis↑, E-cadherin↑, TumCMig↓, MMP2↓, MMP9↓, uPAR↓, ICAM-1↓, VEGF↓, p‑IκB↓, NF-kB↓, NO↓, TumCG↓, TumMeta↓,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP/DDIT3↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2/KDR/Flk1↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1/ATG6↑, IL1β↓, CRP↓, IL10↓, COX2/PTGS2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
85- QC,    Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)
- in-vitro, Pca, PC3
uPA↓, uPAR↓, EGFR↓, NRAS↓, Jun↓, NF-kB↓, β-catenin/ZEB1↓, p38↑, MAPK↑, cJun↓, cFos↓, Raf↓, TumCI↓, TumCMig↓,
3079- RES,    Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action
- Review, Var, NA
angioG↓, TumMeta↓, ChemoSen↑, NADPH↑, SIRT1↑, NF-kB↓, NLRP3↓, Dose↝, COX2/PTGS2↓, MMP9↓, PGE2↓, TIMP1↑, TIMP2↑, Sp1/3/4↓, p‑JNK↓, uPAR↓, ROS↓, CXCR4↓, IL6↓, Gli1↓, *ROS↓, *GSTs↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *GSH↑, Synergy↑, Synergy↑, Synergy↑,
2125- TQ,    Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
- in-vitro, RCC, RCC4 - in-vitro, RCC, Caki-1
Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX/CA9↓, PDK1 / PDPK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 3,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 2,   compIII↓, 1,   EGF↓, 1,   mtDam↑, 1,   OXPHOS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

i-ATP↓, 1,   CAIX/CA9↓, 1,   Glycolysis↓, 1,   e-lactateProd↓, 1,   LDHA↓, 1,   NADPH↑, 1,   PDK1 / PDPK1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↑, 3,   BAD↑, 1,   Bak↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   Casp3↓, 1,   Casp9↑, 1,   Cyt‑c↑, 2,   DR5↑, 1,   FasL↑, 1,   FasL⇅, 1,   MDM2↓, 1,   p38↑, 2,   PUMA↓, 1,   survivin↓, 1,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   EGFR↓, 4,   p‑EGFR↓, 1,   ERK↓, 1,   ERK↑, 1,   FGFR1↓, 1,   HER2/EBBR2↓, 1,   IGFR↓, 1,   IKKα↓, 1,   p‑IκB↓, 1,   p‑JAK1↓, 1,   JAK2↓, 1,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 2,   mTOR↓, 3,   NRAS↓, 1,   PI3K↓, 2,   PTEN↑, 1,   Raf↓, 2,   RAS↓, 2,   Sp1/3/4↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   cMyc↓, 2,   DNMTs↓, 1,   EZH2↓, 1,   FOXM1↓, 1,   HDAC↓, 1,   HDAC6↓, 1,   miR-21↑, 1,   miR-34a↑, 1,   MTA2↓, 1,   other↝, 1,   SOX4↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3B-II↑, 1,   TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   PARP↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↑, 1,   CDK4↓, 2,   CDK6↓, 1,   CDKN1C/p57↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 1,   p27/CDKN1B↓, 1,   p‑pRB↓, 1,   TumCCA↓, 1,   TumCCA↑, 4,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   CSCs↓, 2,   FGF↓, 1,   Gli1↓, 1,   IGFBP3↑, 1,   Jun↓, 1,   Let-7↑, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   Shh↓, 1,   TumCG↓, 2,   TumCP↓, 3,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   E-cadherin↑, 2,   EMT↓, 2,   FAK↓, 1,   Fibronectin↓, 1,   MMP2↓, 6,   MMP3↓, 1,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 1,   PDGF↓, 1,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 2,   TSP-1↑, 1,   TumCI↓, 4,   TumCMig↓, 6,   TumMeta↓, 3,   uPA↓, 7,   uPAR↓, 11,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   Hif1a↓, 1,   NO↓, 1,   VEGF↓, 4,   VEGFR1↓, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   GLUT1↓, 1,   MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   CXCR4↓, 2,   ICAM-1↓, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 4,   Inflam↓, 1,   IRAK1↓, 1,   NF-kB↓, 7,   NLRP3↓, 2,   PGE2↓, 1,   PSA↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AR↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   Dose↝, 3,   eff↑, 1,   eff↝, 1,   selectivity↑, 1,   Synergy↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   CRP↓, 1,   EGFR↓, 4,   p‑EGFR↓, 1,   EZH2↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 4,   LDH↑, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   chemoPv↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 179

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   GSTs↑, 2,   lipid-P↓, 1,   NQO1↑, 1,   ROS↓, 2,   SOD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↝, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,  

Functional Outcomes(tgid=23) ⓘ

Stroke↓, 1,  
Total Targets: 15

Scientific Paper Hit Count for: uPAR, Urokinase-type plasminogen activator receptor
2 Diindolylmethane
2 Quercetin
1 Benzyl isothiocyanate
1 Phenethyl isothiocyanate
1 Allyl isothiocyanate
1 Isothiocyanates
1 Black Rice, Oryza sativa
1 Indole-3-carbinol
1 Morin
1 Nimbolide
1 Marjoram (Origanum majorana)
1 Resveratrol
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:429  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page